Eurobio Scientific Société anonyme (ALERS.PA)
EUR 25.3
(1.2%)
EUR 25.3
(1.2%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 81.23 Million EUR | -13.89% |
| 2022 | 94.33 Million EUR | 1246.15% |
| 2021 | 7 Million EUR | -36.14% |
| 2020 | 10.97 Million EUR | 41.93% |
| 2019 | 7.73 Million EUR | -37.7% |
| 2018 | 12.41 Million EUR | 8.51% |
| 2017 | 11.43 Million EUR | 518.94% |
| 2016 | 1.84 Million EUR | 225.93% |
| 2015 | 567 Thousand EUR | -37.14% |
| 2014 | 902 Thousand EUR | -35.53% |
| 2013 | 1.39 Million EUR | -34.13% |
| 2012 | 2.12 Million EUR | 0.0% |
| 2011 | - EUR | -100.0% |
| 2010 | 15 Thousand EUR | -81.48% |
| 2009 | 81 Thousand EUR | -99.41% |
| 2008 | 13.73 Million EUR | -0.44% |
| 2007 | 13.79 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 74.56 Million EUR | 0.0% |
| 2023 Q2 | 87.98 Million EUR | 0.0% |
| 2023 FY | 81.23 Million EUR | -13.89% |
| 2023 Q4 | 81.23 Million EUR | 0.0% |
| 2022 Q4 | 94.33 Million EUR | 0.0% |
| 2022 FY | 94.33 Million EUR | 1246.15% |
| 2022 Q2 | 5.41 Million EUR | 0.0% |
| 2021 Q4 | 7 Million EUR | 0.0% |
| 2021 FY | 7 Million EUR | -36.14% |
| 2021 Q2 | 8.78 Million EUR | 0.0% |
| 2020 FY | 10.97 Million EUR | 41.93% |
| 2020 Q4 | 10.97 Million EUR | 0.0% |
| 2020 Q2 | 12.9 Million EUR | 0.0% |
| 2019 Q2 | 10.62 Million EUR | 0.0% |
| 2019 Q4 | 7.73 Million EUR | 0.0% |
| 2019 FY | 7.73 Million EUR | -37.7% |
| 2018 Q4 | 12.41 Million EUR | 0.0% |
| 2018 FY | 12.41 Million EUR | 8.51% |
| 2018 Q2 | 10.41 Million EUR | 0.0% |
| 2017 Q4 | 11.43 Million EUR | 0.0% |
| 2017 FY | 11.43 Million EUR | 518.94% |
| 2017 Q2 | 11.11 Million EUR | 0.0% |
| 2016 Q4 | 1.84 Million EUR | 0.0% |
| 2016 Q2 | 649 Thousand EUR | 0.0% |
| 2016 FY | 1.84 Million EUR | 225.93% |
| 2015 FY | 567 Thousand EUR | -37.14% |
| 2015 Q4 | 567 Thousand EUR | 0.0% |
| 2015 Q2 | 735 Thousand EUR | 0.0% |
| 2014 Q4 | 902 Thousand EUR | 0.0% |
| 2014 FY | 902 Thousand EUR | -35.53% |
| 2014 Q2 | 1.14 Million EUR | 0.0% |
| 2013 Q2 | 1.7 Million EUR | 0.0% |
| 2013 FY | 1.39 Million EUR | -34.13% |
| 2013 Q4 | 1.52 Million EUR | 0.0% |
| 2012 Q4 | 2.12 Million EUR | 325.23% |
| 2012 Q1 | 499.5 Thousand EUR | 0.0% |
| 2012 FY | 2.12 Million EUR | 0.0% |
| 2012 Q2 | - EUR | -100.0% |
| 2012 Q3 | 499.5 Thousand EUR | 0.0% |
| 2011 Q1 | - EUR | -100.0% |
| 2011 FY | - EUR | -100.0% |
| 2011 Q4 | - EUR | 0.0% |
| 2011 Q3 | - EUR | -100.0% |
| 2011 Q2 | 6.52 Million EUR | 0.0% |
| 2010 Q1 | - EUR | -100.0% |
| 2010 Q2 | 6.55 Million EUR | 0.0% |
| 2010 Q3 | - EUR | -100.0% |
| 2010 Q4 | 15 Thousand EUR | 0.0% |
| 2010 FY | 15 Thousand EUR | -81.48% |
| 2009 Q4 | 81 Thousand EUR | 0.0% |
| 2009 Q3 | - EUR | 0.0% |
| 2009 Q2 | - EUR | 0.0% |
| 2009 Q1 | - EUR | -100.0% |
| 2009 FY | 81 Thousand EUR | -99.41% |
| 2008 Q3 | 3.38 Million EUR | 0.0% |
| 2008 Q1 | 3.38 Million EUR | 0.0% |
| 2008 Q2 | 3.38 Million EUR | 0.0% |
| 2008 FY | 13.73 Million EUR | -0.44% |
| 2008 Q4 | 3.38 Million EUR | 0.0% |
| 2007 Q2 | 3.38 Million EUR | 0.0% |
| 2007 FY | 13.79 Million EUR | 0.0% |
| 2007 Q1 | 3.38 Million EUR | 0.0% |
| 2007 Q4 | 3.38 Million EUR | 0.0% |
| 2007 Q3 | 3.38 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Affluent Medical SA | 14.41 Million EUR | -463.674% |
| Bluelinea Société Anonyme | 2.11 Million EUR | -3748.608% |
| Carmat SA | 57.64 Million EUR | -40.906% |
| Diagnostic Medical Systems S.A. | 13.19 Million EUR | -515.48% |
| Euromedis Groupe | 5.08 Million EUR | -1497.123% |
| Ikonisys S.A. | 3.2 Million EUR | -2432.532% |
| Implanet S.A. | 1.38 Million EUR | -5777.786% |
| Median Technologies SA | 21.64 Million EUR | -275.374% |
| SpineGuard SA | 1.87 Million EUR | -4230.802% |
| Theraclion SA | 1.95 Million EUR | -4064.121% |
| Euroapi S.A. | 15.5 Million EUR | -424.071% |
| Guerbet SA | 360.51 Million EUR | 77.468% |